CR20200285A - Conjugados anticuerpo anti-cd40-fármaco - Google Patents

Conjugados anticuerpo anti-cd40-fármaco

Info

Publication number
CR20200285A
CR20200285A CR20200285A CR20200285A CR20200285A CR 20200285 A CR20200285 A CR 20200285A CR 20200285 A CR20200285 A CR 20200285A CR 20200285 A CR20200285 A CR 20200285A CR 20200285 A CR20200285 A CR 20200285A
Authority
CR
Costa Rica
Prior art keywords
sup
drug conjugates
antibody drug
formula
further provided
Prior art date
Application number
CR20200285A
Other languages
English (en)
Inventor
Wendy Waegell
Michael J Mcpherson
Christopher C Marvin
Olivia A Perng
Claire L Ihle
Lu Wang
Adrian D Hobson
Shaughn H Bryant
Axel Hernandez Jr
Ling C Santora
Jason Z Oh
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CR20200285A publication Critical patent/CR20200285A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p> </p> <p>En la presente se proporcionan conjugados anticuerpo anti-CD40-fármaco que comprenden un radical de la Fórmula (<strong>I</strong>), en donde R1, R2 y R3 son como se definen en la presente. Además se proporcionan conjugados anticuerpo anti-CD40-fármaco de la Fórmula (<strong>II</strong>), en donde Z, R, AA1, AA2, AA3, m, p, q, n, w, R1, R2 y R3 son como se definen en la presente. Además se proporcionan composiciones farmacéuticas y kits de estas, y métodos para usarlos</p>
CR20200285A 2017-12-01 2018-11-29 Conjugados anticuerpo anti-cd40-fármaco CR20200285A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762593807P 2017-12-01 2017-12-01
US201762595045P 2017-12-05 2017-12-05
PCT/IB2018/059480 WO2019106608A1 (en) 2017-12-01 2018-11-29 Anti-cd40 antibody drug conjugates

Publications (1)

Publication Number Publication Date
CR20200285A true CR20200285A (es) 2020-09-04

Family

ID=66663861

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200285A CR20200285A (es) 2017-12-01 2018-11-29 Conjugados anticuerpo anti-cd40-fármaco

Country Status (19)

Country Link
US (1) US20220265842A1 (es)
EP (1) EP3716982A4 (es)
JP (1) JP2021504430A (es)
KR (1) KR20200095493A (es)
CN (1) CN111465399A (es)
AU (1) AU2018374633A1 (es)
BR (1) BR112020010691A2 (es)
CA (1) CA3081559A1 (es)
CL (1) CL2020001442A1 (es)
CR (1) CR20200285A (es)
DO (1) DOP2020000119A (es)
EC (1) ECSP20034868A (es)
IL (1) IL274650A (es)
MX (1) MX2020005465A (es)
PE (1) PE20201464A1 (es)
PH (1) PH12020550551A1 (es)
RU (1) RU2020117156A (es)
SG (1) SG11202004865SA (es)
WO (1) WO2019106608A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021008305A (es) * 2019-01-11 2021-08-24 Novartis Ag Anticuerpos anti-cd40 para el uso en el tratamiento de hidradenitis supurativa.
CN116761820A (zh) * 2021-02-04 2023-09-15 上海森辉医药有限公司 糖皮质激素受体激动剂的药物偶联物及其在医药上的应用
TW202304462A (zh) * 2021-03-23 2023-02-01 美商美國禮來大藥廠 糖皮質素受體激動劑
AR125079A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas de receptores de glucocorticoides sustituidos con carboxi
EP4365183A1 (en) * 2021-06-24 2024-05-08 Jiangsu Simcere Pharmaceutical Co., Ltd. Steroid compound, and pharmaceutical composition thereof and use thereof
EP4393937A1 (en) * 2021-08-26 2024-07-03 Duality Biologics (Suzhou) Co., Ltd. Steroid compound and conjugate thereof
TW202327620A (zh) * 2021-09-14 2023-07-16 大陸商映恩生物製藥（蘇州）有限公司 一種抗炎症的化合物及其用途
US12121589B2 (en) 2022-06-16 2024-10-22 Abbvie Biotherapeutics Inc. Anti-CD19 antibody drug conjugates
WO2024020164A2 (en) 2022-07-21 2024-01-25 Firefly Bio, Inc. Glucocorticoid receptor agonists and conjugates thereof
WO2024064779A1 (en) * 2022-09-22 2024-03-28 Eli Lilly And Company Glucocorticoid receptor agonists
WO2024140903A1 (zh) * 2022-12-28 2024-07-04 苏州盛迪亚生物医药有限公司 一种cd40结合分子的组合物及医药用途
WO2024140917A1 (zh) * 2022-12-28 2024-07-04 上海盛迪医药有限公司 抗cd40抗体药物偶联物、其制备方法及其医药用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101295998B1 (ko) * 2007-11-30 2013-08-13 화이자 리미티드 신규한 글루코코티코이드 수용체 작용제
US8524697B2 (en) * 2007-12-21 2013-09-03 Merck Sharp & Dohme Corp. C20-C21 substituted glucocorticoid receptor agonists
AU2012249454B2 (en) * 2011-04-29 2016-03-24 Apexigen, Inc. Anti-CD40 antibodies and methods of use
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
WO2015153401A1 (en) * 2014-04-04 2015-10-08 Merck Sharp & Dohme Corp Phosphate based linkers for intracellular delivery of drug conjugates
BR112017025693A2 (pt) * 2015-05-29 2018-08-14 Abbvie Inc. anticorpos anti-cd40 e seus usos

Also Published As

Publication number Publication date
EP3716982A1 (en) 2020-10-07
KR20200095493A (ko) 2020-08-10
WO2019106608A1 (en) 2019-06-06
AU2018374633A1 (en) 2020-05-21
PE20201464A1 (es) 2020-12-17
EP3716982A4 (en) 2021-08-11
ECSP20034868A (es) 2020-08-31
US20220265842A1 (en) 2022-08-25
IL274650A (en) 2020-06-30
BR112020010691A2 (pt) 2020-11-10
CN111465399A (zh) 2020-07-28
CL2020001442A1 (es) 2020-09-11
DOP2020000119A (es) 2020-08-31
JP2021504430A (ja) 2021-02-15
CA3081559A1 (en) 2019-06-06
SG11202004865SA (en) 2020-06-29
RU2020117156A (ru) 2022-01-04
PH12020550551A1 (en) 2021-03-22
MX2020005465A (es) 2020-09-07

Similar Documents

Publication Publication Date Title
CR20200285A (es) Conjugados anticuerpo anti-cd40-fármaco
MX2021009259A (es) Conjugados de il-2 y metodos de uso del mismo.
PH12021500014A1 (en) Fused ring compounds
MX2020002183A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos.
CA2999253C (en) Heterocyclic compounds and uses thereof
EA202091508A1 (ru) 6-азаиндольные соединения
EA202091484A1 (ru) 4-азаиндольные соединения
CL2021000073A1 (es) Inhibidores de tgfß1 selectivos de isoforma, de alta afinidad y usos de los mismos
MX2021010314A (es) Derivados de tiazol como inhibidores de la secreción de proteínas.
EA202091530A1 (ru) Диазаиндольные соединения
PH12020551716A1 (en) Anti-ror antibody constructs
MX2020012679A (es) Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos.
EA201991700A1 (ru) Селективные ингибиторы jak1
CR20200550A (es) Formulaciones de inmunoconjugado anti-cd79b estables
MX2022010515A (es) Conjugacion mediada por transglutaminasa.
MX2020006093A (es) Compuestos de indol eter sustituidos.
MX2020010116A (es) Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk).
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции
PH12021551058A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
BR112019008606A2 (pt) inibidores de interações de mtor-deptor e métodos de uso dos mesmos
PH12021550323A1 (en) Dendrimer formulations